FIGURE 1.
Potential framework for identifying patients without baseline heart failure or established atherosclerotic cardiovascular disease who may benefit from sodium-glucose cotransporter-2 inhibitors. aSaxagliptin and alogliptin. bIncluding neuropathy, retinopathy, or nephropathy. ASCVD, atherosclerotic cardiovascular disease; HbA1c, glycated hemoglobin; NTproBNP, N-terminal probrain natriuretic peptide; SGLT-2, sodium-glucose cotransporter-2; TZD, thiazolidinedione.